TY - JOUR
KW - Adult
KW - Buprenorphine/therapeutic use
KW - Community Health Services/methods
KW - Drug Combinations
KW - Female
KW - Humans
KW - Insurance, Health
KW - Male
KW - Massachusetts
KW - Middle Aged
KW - Multivariate Analysis
KW - Naloxone/therapeutic use
KW - Narcotic Antagonists/therapeutic use
KW - Opioid-Related Disorders/drug therapy
KW - Outpatient Clinics, Hospital
KW - Primary Health Care/methods
KW - Self-Help Groups
KW - Treatment Outcome
AU - I. L. Mintzer
AU - M. Eisenberg
AU - M. Terra
AU - C. MacVane
AU - D. U. Himmelstein
AU - S. Woolhandler
A1 - 
AB - PURPOSE: Office-based treatment of opioid addiction with a combination of buprenorphine and naloxone was approved in 2002. Efficacy of this treatment in non-research clinical settings has not been studied. We examined the efficacy and practicality of buprenorphine-naloxone treatment in primary care settings. METHODS: We studied a cohort of 99 consecutive patients enrolled in buprenorphine-naloxone treatment for opioid dependence at 2 urban primary care practices: a hospital-based primary care clinic, and a primary care practice in a free-standing neighborhood health center. The primary outcome measure was sobriety at 6 months as judged by the treating physician based on periodic urine drug tests, as well as frequent physical examinations and questioning of the patients about substance use. RESULTS: Fifty-four percent of patients were sober at 6 months. There was no significant correlation between sobriety and site of care, drug of choice, neighborhood poverty level, or dose of buprenorphine-naloxone. Sobriety was correlated with private insurance status, older age, length of treatment, and attending self-help meetings. CONCLUSIONS: Opioid-addicted patients can be safely and effectively treated in non-research primary care settings with limited on-site resources. Our findings suggest that greater numbers of patients should have access to buprenorphine-naloxone treatment in nonspecialized settings.
BT - Annals of family medicine
C5 - Opioids & Substance Use
CP - 2
CY - United States
DO - 10.1370/afm.665
IS - 2
JF - Annals of family medicine
N2 - PURPOSE: Office-based treatment of opioid addiction with a combination of buprenorphine and naloxone was approved in 2002. Efficacy of this treatment in non-research clinical settings has not been studied. We examined the efficacy and practicality of buprenorphine-naloxone treatment in primary care settings. METHODS: We studied a cohort of 99 consecutive patients enrolled in buprenorphine-naloxone treatment for opioid dependence at 2 urban primary care practices: a hospital-based primary care clinic, and a primary care practice in a free-standing neighborhood health center. The primary outcome measure was sobriety at 6 months as judged by the treating physician based on periodic urine drug tests, as well as frequent physical examinations and questioning of the patients about substance use. RESULTS: Fifty-four percent of patients were sober at 6 months. There was no significant correlation between sobriety and site of care, drug of choice, neighborhood poverty level, or dose of buprenorphine-naloxone. Sobriety was correlated with private insurance status, older age, length of treatment, and attending self-help meetings. CONCLUSIONS: Opioid-addicted patients can be safely and effectively treated in non-research primary care settings with limited on-site resources. Our findings suggest that greater numbers of patients should have access to buprenorphine-naloxone treatment in nonspecialized settings.
PP - United States
PY - 2007
SN - 1544-1717; 1544-1709
SP - 146
EP - 150
EP - 
T1 - Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings
T2 - Annals of family medicine
TI - Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings
U1 - Opioids & Substance Use
U2 - 17389539
U3 - 10.1370/afm.665
VL - 5
VO - 1544-1717; 1544-1709
Y1 - 2007
ER -